Prostate cancer (PCa) is the second leading cause of cancer-related death among men. Prostate-specific antigen (PSA) testing is used in screening programs for early detection with a consequent reduction of PCa-specific mortality at the cost of overdiagnosis and overtreatment of the nonaggressive PCa. Recently, several assays have been commercially developed to implement PCa diagnosis, but they have not been included in both screening and diagnosis of PCa. This review aims to describe the actual and novel commercially available molecular biomarkers that can be used in PCa management to implement and tailor the screening and diagnosis of PCa.
Humans ; Prostatic Neoplasms/genetics* ; Male ; Biomarkers, Tumor/genetics* ; Early Detection of Cancer/methods* ; Prostate-Specific Antigen/blood* ; Molecular Diagnostic Techniques/methods* ; Glutamate Carboxypeptidase II/metabolism*